We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Again Hits Cadila With Warning Over Controls, Recordkeeping Concerns
FDA Again Hits Cadila With Warning Over Controls, Recordkeeping Concerns
The FDA again has slapped India’s Cadila Pharmaceuticals with a warning letter, this time alleging GMP violations — including a lack of quality controls, improper recordkeeping and inadequate investigations — at its Moraiya formulation plant and Ahmedabad API facility.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor